NetraMark.AI

NetraMark offers explainable AI solutions to the Pharma Industry. Delivering insights to optimize trial design, improve success & explain efficacy in subgroups

[NetraMark.AI @NetraMark_AI]

In a @ctrialvanguard interview, @luca__pani discusses using what a #trial reveals to make more informed #decisions before #Phase3; mentioning that #AI-derived #evidence must be scientifically defensible & prospectively testable in #regulatory discussions: https://t.co/xtpuAzGhcu

[NetraMark.AI @NetraMark_AI]

𝙒𝙝𝙖𝙩 𝙞𝙛 𝙩𝙝𝙚 #𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙙𝙧𝙞𝙫𝙞𝙣�� 𝙩𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙧𝙚𝙨𝙥𝙤𝙣𝙨𝙚 𝙖𝙧𝙚 𝙝𝙞𝙙𝙙𝙚𝙣 𝙬𝙞𝙩𝙝𝙞𝙣 𝙩𝙝𝙚 𝙖𝙫𝙚𝙧𝙖𝙜𝙚? How explainable #AI can help #researchers identify clinically meaningful patients on @Clin_Trials's podcast https://t.co/JTunyL9IGs

[NetraMark.AI @NetraMark_AI]

Listen to the latest #podcast episode of @JAMAplusAI at https://t.co/sawpTSHEh5 where Dr. Joseph Geraci discusses applying #AI to small, complex #clinical #datasets & shares lessons learned from #NetraMark's CPIM discussions with the #FDA regarding #NetraAI's novel #technology.

[NetraMark.AI @NetraMark_AI]

Interpreting signal in #clinicaltrial datasets can mean the difference between phase 2 replicating in a pivotal trial, or millions of dollars sunk into a shelved asset. We help sponsors understand what truly happened across #populations in each trial.
#trialanalysis #NetraMark

[NetraMark.AI @NetraMark_AI]

𝘚𝘮𝘢𝘭𝘭𝘦𝘳 𝘵𝘳𝘪𝘢𝘭𝘴. 𝘏𝘢𝘳𝘥𝘦𝘳 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴. Not all #variability in #clinicaltrials is simply noise. Explore why #patientstratification is becoming an essential part of #drugdevelopment at https://t.co/LIfhCuJBeS #PrecisionMedicine #ClinicalResearch

[NetraMark.AI @NetraMark_AI]

Thrilled to announce another new customer agreement! Through our CRO partner, #NetraAI will analyze a Phase 2 #neurodegeneration #clinicaltrial dataset to uncover explainable insights that support future clinical development strategy & #trialdesign.
#clinicaltrials #analysis

[NetraMark.AI @NetraMark_AI]

Don't miss our #AAIC poster presentation Tuesday, 14 July at 10:30 AM & 3:30 PM in London! We'll share how NetraAI uncovered treatment-responsive subgroups in the landmark A4 Solanezumab trial. Request a copy of our poster at https://t.co/olrSOrMszI
#Alzheimers #A4trial #ENDALZ

[NetraMark.AI @NetraMark_AI]

Announcing a new customer agreement for #NetraAI! We'll be supporting a late-stage #CNS #clinicalprogram to help optimize dose selection, identify patient stratification opportunities, & generate #insights to inform future development decisions.
More at https://t.co/dZVO7VHTHj

[NetraMark.AI @NetraMark_AI]

Thank you @ASCPorg for another great #ASCP2026 meeting! Our team enjoyed participating in the plenary panel, 2 days of poster presentations, & networking with other thought leaders in #psychopharmacology. Request our plenary presentation or posters at https://t.co/QYefcaQL7O

[NetraMark.AI @NetraMark_AI]

Our team is getting ready for @ASCPorg's annual meeting next week in Miami! With two posters and a plenary session, we're looking forward to lots of conversations & networking. Chat with our team at https://t.co/QYefcaQL7O
#ASCP2026 #NetraMark

[NetraMark.AI @NetraMark_AI]

Members of NetraMark's team were in Toronto this morning to open the market at the Toronto Stock Exchange! #TSX #NetraMark #AIAI #MarketOpen #Toronto #trading #innovation #AIforclinicaltrials

[NetraMark.AI @NetraMark_AI]

NetraMark opened the market on Tuesday, May 5, 2026! Watch at https://t.co/9YhBODaNL8
#TSX #NetraMark #AIAI #MarketOpen #Toronto #trading #innovation #AIforclinicaltrials

[NetraMark.AI @NetraMark_AI]

#Psychedelics are known to produce mind-expanding experiences where everything feels connected. We asked what if part of that isn't just #brain #chemistry, but involves #quantumphysics? Read our @FrontPharmacol #publication https://t.co/nrvaCrqgGS or news https://t.co/dZVO7VHTHj

[NetraMark.AI @NetraMark_AI]

A new collaboration for NetraAI to analyze a landmark #precisiononcology trial! We aim to uncover clinically actionable #patient #subpopulations & #biomarker-driven #treatment insights to inform future strategies & #clinicaltrialdesign. More at www.netramark.como/press-releases/

[NetraMark.AI @NetraMark_AI]

Today, at the @adpdnet Conference, we showed how #NetraAI uncovered clinically meaningful #treatmentresponder subgroups in the landmark Asymptomatic Alzheimer’s Disease #A4trial, hinting #therapeuticsignals may have been obscured in conventional analyses: https://t.co/YhVOFl1HVp

[NetraMark.AI @NetraMark_AI]

We've signed a new contract with a global biopharmaceutical company to analyze #Phase2 Depression #trialdata,  expanding our portfolio of AI-driven projects in #depression & #CNS disorders. Learn more at https://t.co/UPqbQY6hZh
#clinicaltrials #AIanalysis #NetraAI #pharma

[NetraMark.AI @NetraMark_AI]

NetraMark is going to @adpdnet! See our team members in Copenhagen between sessions or during our poster presentation. #ADPD26 #Alzheimers #Parkinsons #ADPD

[NetraMark.AI @NetraMark_AI]

Today marks the first day of trading on the Toronto Stock Exchange with our ticker: AIAI. Visit https://t.co/Om2BdoMV21 for key details.

[NetraMark.AI @NetraMark_AI]

We are #uplisting to the @tsx_tsxv! This is a significant milestone as we continue to scale #NetraAI. Trading on the #TorontoStockExchange will commence at market open on February 18, 2026. Learn more at https://t.co/dZVO7VHTHj

[NetraMark.AI @NetraMark_AI]

Ontario Research Fund's #ResearchExcellence #Award (ORF-RE) recognizes innovative partnerships driving #research excellence and technological advancements in #Ontario. Learn more about our collaborative work at https://t.co/dZVO7VHTHj
#AI #clincaltrials #Depression #schizophrenia